Blood: China has published new results of allogeneic hematopoietic stem cell transplantation
Recently, researchers from the United States and China published a paper together, to provide a new method for controlling the content of donor dendritic cells in allogeneic hematopoietic stem cell transplantation and subsequently optimizing the balance between graft versus leukemia (GVL) and graft versus host disease (GVHD) by using mouse transplantation model.
Article author is emory university school of medicine, Edmund k. Waller, a professor at first the author is Shanghai jiaotong university, Dr Lu Ying cell differentiation and apoptosis of ministry of education key laboratory, has won the ministry of education of outstanding Ph.D. Thesis, Dr Lu Ying subject with professor Waller group cooperation in recent years, is committed to graft versus leukemia (GVL) and the activity of GVHD.
Graft-versus host disease (GVHD) is the main complication of allogeneic bone marrow transplantation and one of the main causes of death of transplant patients. The development of safe, effective and feasible methods to inhibit GVHD is an urgent problem to improve the success rate of clinical bone marrow transplantation.
In this paper, using mouse transplantation model, the researchers found that injection of donor plasmacytoid dendritic cells can significantly improve the GVL effect in mice, extend the survival time of recipient mice, and inhibit the GVHD effect. Further mechanism studies revealed that IFN- secreted by donor T cells and indoleamine 2,3-dioxygenase produced by dendritic cells play a key role in inhibiting the immune activity of T cells.
This study provides a new method for controlling the content of donor dendritic cells in allogeneic hematopoietic stem cell transplantation and then optimizing the balance between GVL and GVHD. It also provides an important clue for the development of new strategies for separating GVHD and GVL, which has important theoretical and practical significance.
- June 18, 2019Stem cells have been successfully transplanted into the human body for the first time. According to popular science on November 11, luz douai and his team from Pierre and Marie Curie university in Par...view
- June 18, 2019Cell therapy is the fourth largest treatment method after "physical therapy, drug therapy and surgical therapy". It provides patients with incurable cell injury diseases with an additional choice and ...view
- November 27, 2018As a star product of immunotherapy, CAR-T therapy has shown tremendous strength in blood cancer and has been approved by FDA for the treatment of some acute lymphoblastic leukemia (ALL) and specific t...view